Drug Discovery Research: New Frontiers in the Post-Genomic Era

Post Genomics Drug Discovery and Research explores and discusses some of the most important topics in post-genomics life and biopharmaceutical sciences. It provides an introduction to the field, outlining examples of many techniques currently used, as well as those still under development, which are important for the research of biopharmaceutical discovery in the post-genomics era. Integrates several developing and cutting-edge technologies and methods like bioinformatics, experimental therapeutics, and molecular recognition Includes discussion on topics such as: computer-aided ligand design; peptide and protein chemistry and synthesis; synthesis of active natural products; and the use of emerging technologies like proteomics, nanotechnology, or bioengineering. Content: Chapter 1 Molecular Docking and Structure?Based Design (pages 1–23): P. Therese Lang, Tiba Aynechi, Demetri Moustakas, Brian Shoichet, Irwin D. Kuntz, Natasja Brooijmans and Connie M. OshiroChapter 2 Recent Advances in Drug Discovery Research Using Structure?Based Virtual Screening Techniques: Examples of Success for Diverse Protein Targets (pages 24–62): Sutapa Ghosh, Aihua Nie, Jing An and Ziwei HuangChapter 3 Virtual Screening in Drug Discovery (pages 63–88): Malcolm J. McGregor, Zhaowen Luo and Xuliang JiangChapter 4 Computer?Aided Drug Design (pages 89–107): Grace Shiahuy Chen and Ji?Wang ChernChapter 5 Focused Library Design Based on Hit and Target Structures: Method and Application in Drug Discovery (pages 108–124): Weiliang Zhu, Jian Li, Zhen Gong, Hong Liu and Hualiang JiangChapter 6 Beyond Natural Products: Synthetic Analogues of Bryostatin 1 (pages 125–162): Paul A. Wender, Jeremy L. Baryza, Michael K. Hilinski, Joshua C. Horan, Cindy Kan and Vishal A. VermaChapter 7 The Promises and Pitfalls of Small?Molecule Inhibition of Poly(ADP?Ribose) Glycohydrolase (PARG) (pages 163–185): Amanda C. Nottbohm and Paul J. HergenrotherChapter 8 Cyclic ADP?Ribose Analogues with Minimal Structure: Synthesis and Calcium?Release Activity (pages 186–202): Lihe Zhang and Andreas H. GuseChapter 9 Evaluation of Neuroimmunophilin Ligands (pages 203–229): Junhai Xiao, Aihua Nie and Song LiChapter 10 Chiral Drugs and the Associated Asymmetric Synthesis (pages 230–280): Jiange Zhang and Guoqiang LinChapter 11 Alpha?Helix Mimetics in Drug Discovery (pages 281–299): Hang Yin, Gui?In Lee and Andrew D. HamiltonChapter 12 Basic and Translational Research of Chemokine Ligands and Receptors and Development of Novel Therapeutics (pages 300–335): Won?Tak Choi, Yohichi Kumaki, I. M. Krishna Kumar, Jing An, Douglas D. Richman, Joseph G. Sodroski and Ziwei HuangChapter 13 Research Progress in Protein Post?Translational Modification (pages 336–354): Jia Hu, Yanting Guo and Yanmei LiChapter 14 Controlled Release of Antibiotics Encapsulated in Nanoporous Sol–Gel Materials with Tunable Pore Parameters (pages 355–370): Houping Yin, Laura Zheng and Yen WeiChapter 15 Retinoic Acid and Arsenic Trioxide Treatment in Acute Promyelocytic Leukemia: A Model of Oncoprotein Targeted Therapy (pages 371–392): Jian?Hua Tong, Sai?Juan Chen and Zhu ChenChapter 16 2?Chlorodeoxyadenosine (Cladribine): Rational Development of a Novel Chemotherapeutic Agent (pages 393–407): Howard B. Cottam and Dennis A. CarsonChapter 17 Apoptosis?Based Drug Discovery for Cancer (pages 408–438): John C. Reed, Dayong Zhai, Marc Hyer and Kate WelshChapter 18 Mechanism?Based Development of Memantine as a Therapeutic Agent in Treating Alzheimer's Disease and Other Neurologic Disorders: Low?Affinity, Uncompetitive Antagonism with Fast Off?Rate (pages 439–464): Huei?Sheng Vincent Chen and Stuart A. LiptonChapter 19 Bridging Bench to Clinic: Roles of Animal Models for Post?Genomics Drug Discovery on Metabolic Diseases (pages 465–478): Chi?Wai Wong and Ling ChenChapter 20 Stem Cell Research and Applications for Human Therapies (pages 479–506): Prithi Rajan, Kook In Park, Vaclav Ourednik, Jean Pyo Lee, Jamie Imitola, Franz?Joseph Mueller, Yang D. Teng and Evan Snyder